Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors

Inclusion Criteria: * Pathologic (histologic or cytologic) confirmation of metastatic or locally advanced solid tumor. * Patients who have experienced disease progression after receiving appropriate standard / approved chemotherapy and for whom no further standard or palliative treatment measures exist, or who have chosen to decline standard or palliative treatment. * One or more tumors measurable by RECIST criteria. * Karnofsky performance status ≥ 70%. * Recovery from any toxic or other effects of all previous therapy, including radiation, chemotherapy and surgery. * Negative serum or urine pregnancy test result in women of childbearing potential. * For men and women of child-producing potential, agreement to use effective contraception (hormonal or barrier birth control or abstinence) from the time of screening before study entry and throughout study participation. Exclusion Criteria: * Brain metastasis. * New York Heart Association Class III or IV cardiac disease, myocardial infarction, or cardiac arrhythmia requiring medical therapy. * Known allergy to hyaluronidase. * Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions including psychiatric illness) that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor. * Women currently breast feeding. * Concurrent participation in any other interventional therapeutic study.